Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track

Spero Therapeutics, Inc.

2025-Q1 EPS reported -$0.25 revenue$5,874,000

Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.
Cash $48.9M plus $23.75M earned GSK milestone payments provides runway into Q2 2026.
Esther Rajavelu appointed President & CEO effective May 2, 2025; continues as CFO & Treasurer.
Phase 3 PIVOT-PO interim analysis for tebipenem HBr expected Q2 2025; SPR720 program suspended after missing endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.